LRIG1 Enhances Chemosensitivity by Modulating BCL-2 Expression and Receptor Tyrosine Kinase Signaling in Glioma Cells

PURPOSE: Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) are an inhibitor of receptor tyrosine kinases (RTKs) that was discovered in recent years, and many studies showed that LRIG1 is a tumor suppressor gene and may be related to tumor drug resistance. In this study, we explored whet...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Zhentao, Chen, Qianxue, Liu, Baohui, Tian, Daofeng, Zhang, Shenqi, Li, Mingchang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108802/
https://www.ncbi.nlm.nih.gov/pubmed/25048475
http://dx.doi.org/10.3349/ymj.2014.55.5.1196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108802/
https://www.ncbi.nlm.nih.gov/pubmed/25048475
http://dx.doi.org/10.3349/ymj.2014.55.5.1196

Ejemplares similares